Hansa Biopharma AB (publ) (HNSA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and welcome to the HANSA Biopharma interim results and Q1 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please see the conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. And now I turn the conference over to Peter Nicklin, Chairman of the Board, Hansa Biopharma. Please go ahead. Good afternoon and good morning, everybody. Welcome to the Hansa Biopharma conference call to review our Q1 results for 2025. I'm Peter Nicklin, Chairman of the Board of Hansa Biopharma. You'll recollect in June this year, I actually reached my third year anniversary as Chairman of the Board. Joining me today is Adam Ballantyne, Chief Financial Officer, Hito Kaufmann, our Chief R&D Officer, and René Lucander, our newly appointed CEO. Before we turn to the Q1 results, you are most likely aware that earlier today we announced the departure of Sölden Tolstoy, CEO of Hansa Biopharma, effective immediately. Over the course of his tenure with the organization, CERN successfully navigated the company through several key milestones and financial rounds. The board and I certainly appreciate his leadership and commitment to the company and wish him well for any future endeavors. Later in the call, we will hear from Renée, who has been appointed as CEO, effective immediately. Today is her first day at Hanza, and while she is in the room with me here, I trust that you will agree that it would be unfair to ask to host this call with you today. So with that, please turn to slide two. Pl...